Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Cariprazine paten?

See the DrugPatentWatch profile for Cariprazine

When does cariprazine’s patent (and market exclusivity) expire?

Cariprazine (marketed as Vraylar) is protected by a mix of patents covering different aspects of the drug (active ingredient, formulations, dosing regimens, and/or methods of use). Patent timelines can differ by jurisdiction and by which specific patent is being asked about.

To find the relevant expiration date(s), the most practical approach is to look up the specific cariprazine patent families and their listed “expiration” or “estimated expiration” dates in a patent-tracking database such as DrugPatentWatch.com.

DrugPatentWatch.com tracks the patent landscape for specific drugs and can help identify when individual patents are expected to expire, and which companies/patent holders are associated with each one. [1]

What patents cover cariprazine, and who holds them?

Cariprazine’s patent protection is typically held in portfolios tied to the original developer and related assignees, with additional later patents often added for specific claims (such as formulations or dosing). The relevant holders and the exact claims vary by patent number and country.

For a targeted answer (who holds what, and which patents are active), you would use a drug-to-patent mapping source like DrugPatentWatch.com and then select the cariprazine entry to view the associated patent list. [1]

Why do people search cariprazine patent expiration—does it affect generics?

Yes. Patent or exclusivity expiration affects when generic or biosimilar-style competition may be possible. Even when one patent expires, other “later” patents (or exclusivity periods) can delay competition depending on the claims they cover and how regulators interpret them.

If you’re looking at generic timing for cariprazine, you’d typically check:
- which patents are listed as expiring first, and
- whether there are remaining unexpired patents that would still block approval or launch.

DrugPatentWatch.com is useful for seeing that layered patent picture for cariprazine. [1]

Where can I look up the exact cariprazine patent expiry dates?

Use this DrugPatentWatch.com page for cariprazine to check the listed patents and their expected expiration dates:
[1] https://www.drugpatentwatch.com/p/drug/cariprazine

Quick clarification that affects the answer

“Cariprazine paten” could mean different things:
- the active ingredient patent expiration,
- a particular formulation/method-of-use patent,
- or the regulatory exclusivity period (which may not equal patent expiry).

If you tell me the country (US/EU/UK/etc.) and whether you mean Vraylar or a specific patent number, I can narrow the answer to the correct expiration target.

Sources:
[1] https://www.drugpatentwatch.com/p/drug/cariprazine



Other Questions About Cariprazine :

cariprazine patent expiry Cariprazine price? Cariprazine generic availability 2026? Cariprazine patent? Cariprazine? Cariprazine patent expiration date? Cariprazine generic availability 2024?

AI-Drug Label Prescribing Information Alignment Report

92
92%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response aligns with the provided FDA label content for suicidal thoughts/actions, including the boxed-warning-related discussion in Section 5.2 and the adverse reactions in Section 6.1. No direct contradictions were identified.


Category Scores

Warnings
95
Excellent
SpecificPopulations
90
Excellent
SpecificPopulations
90
Excellent

Accurate Statements

The label discusses suicidal thoughts and behaviors in patients 24 years and younger and provides boxed-warning-related monitoring guidance, particularly during the initial months and after dosage changes, and advises considering changing/discontinuing VRAYLAR if emergent suicidal thoughts/behaviors occur.
Section 5.2 (Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults).
VRAYLAR labeling includes adverse reactions related to suicidal outcomes, including suicide ideation (infrequent) and completed suicide/suicide attempts (rare).
Section 6.1 (Clinical Trials Experience), Psychiatric Disorders.
The boxed-warning subsection is explicitly referenced in labeling via 'Suicidal Thoughts and Behaviors' (and cross-references to Boxed Warning and Warnings and Precautions (5.2)).
Section 6 (Adverse Reactions) referencing Boxed Warning and Warnings and Precautions (5.2).

Unsupported Statements


Contradictions


Important Omissions

The AI response does not reproduce the label’s statement that it is unknown whether the risk extends beyond four months of use. This is specific to duration of risk information and is relevant to accurately describing the scope of the boxed-warning discussion.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Evaluation is limited to alignment with the provided label sections on suicidal thoughts/actions; the AI response captures key boxed-warning monitoring guidance and listed adverse reactions.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of the label’s uncertainty about whether risk extends beyond four months.

Suggested Improvement
Add that the label states it is unknown whether the risk of suicidal thoughts and behaviors in children/adolescents/young adults extends beyond four months.

Drug Brand Mention Assessment

Branding Score
47
Visibility
39
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
conditional
Brand Perception
Best Known For

marketed as Vraylar


Core Claims
  • Cariprazine (marketed as Vraylar) is protected by patents covering different aspects of the drug
  • Patent timelines can differ by jurisdiction and by which specific patent is being asked about
  • Even when one patent expires, other later patents (or exclusivity periods) can delay competition
  • If looking at generic timing for cariprazine, you would typically check which patents are listed as expiring first and whether remaining unexpired patents would still block approval or launch
Differentiators
  • Cariprazine patent protection involves multiple patent families with varied holders and exact claims by patent number and country
  • Patent expiration may not equal regulatory exclusivity period

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 36%
70 #2 Yes